Leerink Partners' Rating of Zymeworks on 3/3/2026

On March 3, 2026, Leerink Partners updated its outlook on Zymeworks (NASDAQ:ZYME) with the action "Boost Price Target", setting a price target of $58.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Leerink Partners

DateCompanyAction
11/19/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Boost Price Target
11/19/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
Downgrade
11/19/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Upgrade
11/17/2026
Erasca, Inc. stock logo
ERAS
Erasca
Initiated Coverage
11/17/2026
Viatris Inc. stock logo
VTRS
Viatris
Boost Price Target
11/16/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Boost Price Target
More Ratings From Leerink Partners